Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer

被引：0
作者：
Susanne Taucher
Margaretha Rudas
Robert M. Mader
Michael Gnant
Emanuel Sporn
Peter Dubsky
Sebastian Roka
Thomas Bachleitner
Florian Fitzal
Daniela Kandioler
Catharina Wenzel
Günther G. Steger
Martina Mittlböck
Raimund Jakesz
机构：
[1] Vienna University Medical School,Department of Surgery
[2] Vienna University Medical School,Department of Pathology
[3] Vienna University Medical School,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 82卷
关键词：
breast cancer; core needle biopsy; docetaxel; epirubicin; FISH; HER2/; immunohistochemistry; preoperative treatment; trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background. In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration of anticancer drugs. Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu.
引用
收藏
页码：207 / 213
页数：6
相关论文
共 213 条
[1]  
King CR(1985)Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 974-976
[2]  
Kraus MH(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ Science 235 177-182
[3]  
Aaronson SA(1989) oncogene Science 244 707-712
[4]  
Slamon DJ(2001)Studies of the HER-2/ J Clin Oncol 19 3808-3816
[5]  
Clark GM(1998) proto-oncogene in human breast and ovarian cancer J Clin Oncol 16 2659-2671
[6]  
Wong SG(1998)Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial Mod Pathol 11 259-264
[7]  
Levin WJ(1996)Phase II study of receptorenhanced chemosensitivity using recombinant humanized anti-p185HER2/ Eur J Cancer 32A 1693-1700
[8]  
Ullrich A(2001) monoclonal antibody plus cisplatin in patients with HER2/ Breast Cancer Res Treat 69 13-19
[9]  
McGuire WL(2002)-overexpressing metastatic breast cancer refractory to chemotherapy treatment Am J Surg 184 322-324
[10]  
Slamon DJ(1994)Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Annu Rev Pharmacol Toxicol 34 191-218
12345678910